WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
UNAIDS/WHO 2015 | Reference
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
3rd Edition – July 2017
www.msfaccess.org
Strengthening Community responses to HIv Treatment and Prevention